LETM2: A Potential Drug Target and Biomarker for Fasting and Obesity

Target Name: LETM2

NCBI ID: G137994

LETM2

Other Name(s): Leucine zipper-EF-hand-containing transmembrane protein 1-like | LETM2_HUMAN | leucine zipper-EF-hand containing transmembrane protein 1-like protein | Leucine zipper and EF-hand containing transmembrane protein 2, transcript variant 1 | leucine zipper and EF-hand containing transmembrane protein 2 | LETM1 and EF-hand domain-containing protein 2 | Leucine zipper-EF-hand containing transmembrane protein 1-like protein (LETM2) | SLC55A2 | LETM2 variant 1 | leucine zipper-EF-hand containing transmembrane protein 2 | LETM1 domain-containing protein LETM2, mitochondrial | LETM1 domain-containing protein LETM2, mitochondrial (isoform 1) | Leucine zipper-EF-hand containing transmembrane protein 1-like protein

LETM2: A Potential Drug Target and Biomarker for Fasting and Obesity

LEucine zipper-EF-hand-containing transmembrane protein 1-like (LETM2) is a protein that is expressed in various tissues, including the brain, heart, and muscles. It is a member of the evolutionarily conserved Transmembrane Protein (TMP) family, which includes several other well-known proteins, such as Transthyretin (TTR), which is a major risk factor for cardiovascular disease, and Glycophorin A (GPI-A), which is a protein that is expressed in the liver and has been linked to the development of certain diseases.

LETM2 is characterized by its unique structure, which consists of a long extracellular domain, a short transmembrane region, and a long intracellular tail. This structure allows LETM2 to interact with various cellular signaling pathways, including the TGF-β pathway, which plays a key role in cell growth, differentiation, and obesity.

One of the most interesting aspects of LETM2 is its role in fasting and obesity. LETM2 has been shown to be involved in the regulation of energy metabolism and in the control of body weight. Several studies have shown that LETM2 promotes the growth of fat cells and increases the levels of fat in the body. This may contribute to the development of obesity and type 2 diabetes.

In addition to its role in obesity, LETM2 has also been linked to other diseases. For example, LETM2 has been shown to be involved in the development of certain neurological conditions, such as Alzheimer's disease and Parkinson's disease. It may also be involved in the development of certain cancers, such as breast cancer.

Given the potential role of LETM2 in the development of obesity and other diseases, it is a promising target for drug development. Researchers are currently working to develop small molecules that can inhibit the activity of LETM2 and prevent its contribution to disease. These drugs may have potential applications in treating a range of conditions, including obesity, type 2 diabetes, and certain neurological and psychiatric disorders.

In conclusion, LETM2 is a protein that is expressed in various tissues and is involved in the regulation of energy metabolism and body weight. Its role in the development of obesity and other diseases makes it a promising target for drug development. Further research is needed to fully understand the function of LETM2 and its potential as a drug.

Protein Name: Leucine Zipper And EF-hand Containing Transmembrane Protein 2

The "LETM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LETM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets